lorundrostat
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Mar 13, 2023 (NCT05769608)
Timeline
Indications
Mechanism of action
- Cytochrome P450 11B2INHIBITOR
CYP11B2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)N[C@H]1CC[C@H](NC(=O)CN2CCN(c3nncc(-c4ccc(C)cc4)n3)CC2)CC1- Mol. weight
- 451.58 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095105 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06785454 | Phase 2 | Mar 31, 2025 | Mineralys Therapeutics Inc. |
| NCT06150924 | Phase 2 | Dec 31, 2023 | Mineralys Therapeutics Inc. |
| NCT06153693 | Phase 3 | Nov 22, 2023 | Mineralys Therapeutics Inc. |
| NCT05968430 | Phase 2/Phase 3 (Phase 3) | Jul 14, 2023 | Mineralys Therapeutics Inc. |
| NCT05769608 | Phase 2 | Mar 13, 2023 | Mineralys Therapeutics Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mineralys Therapeutics Inc. | For profit | 5 | 5 | 2 | 2023 |
1 organizations
Page 1 / 1